Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Entera Bio Ltd. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 9.34M | 7.87M | −1.47M (−15.7%) |
| Value | $18.1M | $8.68M | −$9.45M (−52.1%) |
New holders (8)
Institutions that held Entera Bio Ltd. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 131,622 | $146.1K | 0.00% |
| Diadema Partners LP | 23,260 | $25.8K | 0.01% |
| HRT Financial LP | 15,492 | $17.0K | 0.00% |
| JPMorgan Chase & Co | 7,150 | $7.15K | 0.00% |
| Persistent Asset Partners Ltd | 5,881 | $6.53K | 0.00% |
| Morgan Stanley | 400 | $444 | 0.00% |
| Caitong International Asset Management Co., Ltd | 20 | $22 | 0.00% |
| SBI Securities Co., Ltd. | 2 | $2 | 0.00% |
Sold out (4)
Institutions that held Entera Bio Ltd. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 64,910 | $125.9K |
| Superstring Capital Management LP | 17,142 | $33.3K |
| Goldman Sachs Group Inc | 12,327 | $23.9K |
| Gsa Capital Partners LLP | 11,890 | $23.0K |